Treatment | LVDP (mm Hg) | LVEDP (mm Hg) | ||||
Baseline | 60 min reperfusion | 120 min reperfusion | Baseline | 60 min reperfusion | 120 min reperfusion | |
C57BL/6 CON | 66.3 ± 1.5 | 11.9 ± 2.1 | 12.9 ± 1.9 | 4.6 ± 0.3 | 50.6 ± 3.8 | 39.9 ± 3.7 |
IP | 65.9 ± 1.9 | 22.5 ± 2.5* | 22.6 ± 2.3* | 4.3 ± 0.6 | 27.3 ± 3.4* | 16.4 ± 3.4* |
C57BL/6 SB | 70.1 ± 3.8 | 14.5 ± 1.3* | 16.4 ± 1.3 | 6.7 ± 0.7 | 65.9 ± 1.6* | 48.6 ± 5.0 |
BIO | 64.6 ± 2.5 | 15.0 ± 6.4 | 13.0 ± 5.3 | 6.1 ± 0.6 | 55.9 ± 9.0 | 45.9 ± 7.7 |
GSK3ab KI CON | 66.3 ± 2.7 | 32.3 ± 3.6† | 28.3 ± 2.7† | 5.7 ± 0.5 | 34.6 ± 4.4† | 29.9 ± 3.6† |
IP | 69.7 ± 3.6 | 13.7 ± 4.3 | 14.4 ± 10.7 | 6.6 ± 0.4 | 14.1 ± 2.1*† | 11.4 ± 1.2*† |
GSK3abWT CON | 69.7 ± 3.6 | 13.7 ± 4.3 | 14.4 ± 10.7 | 6.6 ± 0.4 | 57.6 ± 6.1 | 49.6 ± 6.0 |
IP | 68.6 ± 2.6 | 19.4 ± 4.3 | 21.9 ± 4.2 | 5.4 ± 0.6 | 43.3 ± 7.1 | 33.4 ± 7.5 |
BIO, 6-bromoindirubin-3′-oxime; CON, uninterrupted perfusion; IP, ischaemic preconditioning; LVDP, left ventricular developed pressure; LVEDP, left ventricular end-diastolic pressure; SB, SB216763; WT, wild type. *p< 0.05 versus CON; †p< 0.05 versus WT.